Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2020 06:50 ET | Source: Sublimity Therapeutics Limited

Sublimity To Present at Three Life science Investment Conferences

SOLANA BEACH, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a biopharmaceutical company focused on creating meaningful new treatments for GI and immunological diseases, today...
February 27, 2020 06:00 ET | Source: Sublimity Therapeutics Limited

Sublimity To Present at Three Life science Investment Conferences

SOLANA BEACH, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a biopharmaceutical company focused on creating meaningful new treatments for GI and immunological diseases, today...
January 07, 2019 09:00 ET | Source: Sublimity Therapeutics Limited

Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)

Company also Receives Ireland Authorization and Health Canada Clearance Phase 2b Clinical Trial of ST-0529 for the Treatment of Ulcerative Colitis to Launch This Month SAN DIEGO, Jan. 07, 2019 ...
July 30, 2018 06:00 ET | Source: Sublimity Therapeutics Limited

Sublimity Therapeutics Appoints Jesse W. Hall as Chief Medical Officer

DUBLIN, Ireland, July 30, 2018 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a specialty pharmaceutical company focused on the treatment of ulcerative colitis, today announced the appointment of...
May 22, 2018 06:00 ET | Source: Sublimity Therapeutics Limited

Sublimity Therapeutics Closes US$64 Million Financing to Fund Development of New Oral Ulcerative Colitis Drug Candidate

DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Sublimity Therapeutics Limited (formerly Sigmoid Pharma Limited), a specialty pharmaceutical company focused on the treatment of ulcerative colitis,...